Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on its subsidiary's obtaining the renewed "Drug Production License"
Securities code: 600671 Securities abbreviation: Tianmu Pharmaceutical Announcement number: Lin 2025-051 Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement on the Subsidiary Obtaining the Reissued "Drug Production License"
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Hangzhou Tianmushan Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") learned that the company's subsidiary Huangshan Tianmu Mint Pharmaceutical Co., Ltd. (hereinafter referred to as "Huangshan Mint") recently received a renewed "Drug Production License" (license number: Anhui 20160184) from the Anhui Provincial Food and Drug Administration. The renewed "Drug Production License" is valid until December 31, 2030. The details are as follows:
1. Main information of "Drug Production License"
Company name: Huangshan Tianmu Mint Pharmaceutical Co., Ltd.
License number: Anhui 20160184
Social credit code: 913410007935839891
Category code: Dz
Registered address: No. 1 Jiulong Avenue, Huangshan Jiulong Low Carbon Economic Park, Tunxi District, Huangshan City, Anhui Province Legal representative: Li Feng
Person in charge of the company: Li Feng
Quality manager: Hong Wenping
Valid until: December 31, 2030
Production address and production scope:
No. 1, Jiulong Avenue, Huangshan Jiulong Low-Carbon Economic Park, Tunxi District, Huangshan City, Anhui Province: API (menthol and mint oil)***
2. Impact on the company
The company's subsidiary Huangshan Mint is renewing its "Drug Production License" this time because the original production license is about to expire. The acquisition of the new license ensures the normal production and operation of Huangshan Mint and will not have a significant impact on the company's operating performance. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
November 6, 2025